Brokerages Set Enovis Co. (NYSE:ENOV) Target Price at $67.00

Enovis Co. (NYSE:ENOV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $67.00.

A number of equities analysts have issued reports on ENOV shares. JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 target price for the company. Evercore ISI decreased their target price on Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. cut their target price on Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $65.00 target price on shares of Enovis in a report on Thursday, November 7th.

Institutional Investors Weigh In On Enovis

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janney Montgomery Scott LLC increased its holdings in Enovis by 18.6% in the first quarter. Janney Montgomery Scott LLC now owns 4,879 shares of the company's stock valued at $305,000 after purchasing an additional 765 shares during the last quarter. US Bancorp DE grew its holdings in Enovis by 3.5% during the first quarter. US Bancorp DE now owns 13,043 shares of the company's stock valued at $815,000 after purchasing an additional 447 shares during the period. Pitcairn Co. increased its stake in Enovis by 6.8% in the first quarter. Pitcairn Co. now owns 6,036 shares of the company's stock valued at $377,000 after purchasing an additional 386 shares in the last quarter. Keeley Teton Advisors LLC raised its holdings in Enovis by 6.8% in the first quarter. Keeley Teton Advisors LLC now owns 6,936 shares of the company's stock worth $433,000 after purchasing an additional 441 shares during the period. Finally, Magnetar Financial LLC boosted its position in shares of Enovis by 10.9% during the first quarter. Magnetar Financial LLC now owns 662,752 shares of the company's stock worth $41,389,000 after purchasing an additional 65,319 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Stock Down 1.1 %

Shares of Enovis stock traded down $0.50 on Wednesday, reaching $44.78. 514,320 shares of the company were exchanged, compared to its average volume of 580,923. The stock's 50 day moving average price is $42.54 and its 200-day moving average price is $45.04. The company has a market cap of $2.50 billion, a P/E ratio of -20.45 and a beta of 1.91. Enovis has a 1-year low of $38.27 and a 1-year high of $65.03. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis's quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. As a group, equities analysts forecast that Enovis will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.